A new study published in the open-access journal PLoS Neglected Tropical Diseases on September 6th presents a key advance in developing a safer cure for sleeping sickness. Led by Professor Peter Kennedy, researchers at the University of Glasgow's Institute for Infection, Immunology and Inflammation have created a version of the drug most commonly used to treat sleeping sickness which can be administered orally in pill form.
Sleeping sickness – or human African trypanosomiasis (HAT) – is a neglected tropical disease of major importance. Transmitted by the tsetse fly and caused by the trypanosome parasite, sleeping sickness is invariably fatal if left untreated. Once the disease has crossed the blood-brain barrier and entered the central nervous system the most commonly used treatment is an intravenous course of the arsenic-based drug melarsoprol. Because melarsoprol has a low solubility in water, it is dissolved in propylene glycol and administered intravenously. The result is a highly-toxic drug that kills five per cent of patients receiving it and leaves many others permanently brain-damaged.
Researchers at the University of Glasgow combined melarsoprol with cyclodextrins – molecules that surrounded the drug allowing it to be administered orally, increasing its solubility and releasing the drug more slowly in the gut. In laboratory tests the altered drug was shown to retain its ability to kill the infection, and was able to cure mice infected with the parasite after a seven-day daily oral dosing schedule. The drug cleared parasites from the brain and restored normal blood-brain barrier integrity.
According to Prof. Kennedy, "This new research is the most clinically important in the 20 years of our trypanosome research group. It has the potential of a major therapeutic advance and if it is equally effective in humans then it would also have a significant socio-economic impact because the duration of inpatient treatment would be shorter and some patients might even be eventually treated at home."
Prof Kennedy added: "You always have to be very cautious when extrapolating results from mouse models to the human disease but there are several reasons why we are quietly optimistic that this may very well work in humans too.
PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS NEGLECTED TROPICAL DISEASES (www.plosntds.org) AS THE SOURCE FOR THIS ARTICLE AND PROVIDE A LINK TO THE FREELY AVAILABLE TEXT. THANK YOU.
PLoS Neglected Tropical Diseases is an open-access, peer-reviewed journal published weekly by the Public Library of Science (PLoS).
EMBARGO in place until: Tuesday, September 6th, 2011, 2pm Pacific/5pm Eastern Time
FINANCIAL DISCLOSURE: This research was funded by the Medical Research Council (G0601059, http://www.mrc.ac.uk/index.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
COMPETING INTERESTS: The authors have declared that no competing interests exist.
PLEASE ADD THIS LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.plos.org/10.1371/journal.pntd.0001308 (link will go live upon embargo lift)
CITATION: Rodgers J, Jones A, Gibaud S, Bradley B, McCabe C, et al. (2011) Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis. PLoS Negl Trop Dis 5(9): e1308. doi:10.1371/journal.pntd.0001308
CONTACT: Stuart Forsyth or Ross Barker at the University of Glasgow Media Relations office, tel 0141 330 3535, email email@example.com / firstname.lastname@example.org
This press release refers to an upcoming article in PLoS Neglected Tropical Diseases. The release is provided by the article authors. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.
PLoS Journals publish under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits free reuse of all materials published with the article, so long as the work is cited (e.g., Kaltenbach LS et al. (2007) Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genet 3(5): e82. doi:10.1371/journal.pgen.0030082). No prior permission is required from the authors or publisher. For queries about the license, please contact the relative journal contact indicated here: http://www.plos.org/journals/embargopolicy.php
About PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases (http://www.plosntds.org/) is a peer-reviewed, open-access journal devoted to the pathology, epidemiology, prevention, treatment, and control of the neglected tropical diseases, as well as public policy relevant to this group of diseases. All works published in PLoS Neglected Tropical Diseases are open access, which means that everything is immediately and freely available subject only to the condition that the original authorship and source are properly attributed. The Public Library of Science uses the Creative Commons Attribution License, and copyright is retained by the authors.
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.